Floatz logo

Igf-Methotrexate Conjugate

Anemia, Refractory, With Excess of Blasts

IGF Oncology, LLCunclassifiedPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Anemia, Refractory, With Excess of Blasts cohort.

Asset / SponsorPhaseRating
Brentuximab Vedotin
Seagen Inc.
Phase 2B
Treg Cells
Masonic Cancer Center, University of Minnesota
Phase 1/2CCC
IMMUNOGLOBULIN G1 ANTI-(HUMAN CD33 (ANTIGEN)) (HUMAN-MOUSE MONOCLONAL HUM195 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL HUM195 .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 1CC
GELONIN (NON-GLYCOSYLATED)
M.D. Anderson Cancer Center
Phase 1CC

Same molecule, other indications

Igf-Methotrexate Conjugate is also rated in:

Leukemia, Myelomonocytic, ChronicDormant
CCC
Indicative ·
48 / 100
View asset →
thoracic cancerDormant
CC
Indicative ·
47 / 100
View asset →
malignant urinary system neoplasmDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →